Samuel Y. Lee BA , Megan E. Paul BA , Anne L. Coleman MD, PhD , Ken Kitayama MD, PhD , Fei Yu PhD , Deyu Pan MS , Victoria L. Tseng MD, PhD
{"title":"我们所有人研究计划中他汀类药物的使用与青光眼之间的关系。","authors":"Samuel Y. Lee BA , Megan E. Paul BA , Anne L. Coleman MD, PhD , Ken Kitayama MD, PhD , Fei Yu PhD , Deyu Pan MS , Victoria L. Tseng MD, PhD","doi":"10.1016/j.ogla.2024.07.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate associations between statin use and glaucoma in the 2017 to 2022 <em>All of Us</em> (<em>AoU</em>) Research Program.</div></div><div><h3>Design</h3><div>Cross-sectional, population-based.</div></div><div><h3>Participants</h3><div>79 742 adult participants aged ≥40 years with hyperlipidemia and with electronic health record (EHR) data in the <em>AoU</em> database.</div></div><div><h3>Methods</h3><div>Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by <em>AoU</em>. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.</div></div><div><h3>Main Outcome Measures</h3><div>Any glaucoma as defined by International Classification of Diseases codes found in EHR data.</div></div><div><h3>Results</h3><div>Of 79 742 individuals with hyperlipidemia in <em>AoU</em>, there were 6365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin nonuse (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01–1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, <em>P</em> value < 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05–1.82) and high (aOR = 1.37, 95% CI = 1.09–1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60 to 69 years (aOR = 1.28, 95% CI = 1.05–1.56).</div></div><div><h3>Conclusions</h3><div>Statin use was associated with increased glaucoma likelihood in the overall adult <em>AoU</em> population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60 to 69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one’s lipid profile and age.</div></div><div><h3>Financial Disclosures</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 6","pages":"Pages 563-571"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Associations between Statin Use and Glaucoma in the All of Us Research Program\",\"authors\":\"Samuel Y. Lee BA , Megan E. Paul BA , Anne L. Coleman MD, PhD , Ken Kitayama MD, PhD , Fei Yu PhD , Deyu Pan MS , Victoria L. Tseng MD, PhD\",\"doi\":\"10.1016/j.ogla.2024.07.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>To investigate associations between statin use and glaucoma in the 2017 to 2022 <em>All of Us</em> (<em>AoU</em>) Research Program.</div></div><div><h3>Design</h3><div>Cross-sectional, population-based.</div></div><div><h3>Participants</h3><div>79 742 adult participants aged ≥40 years with hyperlipidemia and with electronic health record (EHR) data in the <em>AoU</em> database.</div></div><div><h3>Methods</h3><div>Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by <em>AoU</em>. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.</div></div><div><h3>Main Outcome Measures</h3><div>Any glaucoma as defined by International Classification of Diseases codes found in EHR data.</div></div><div><h3>Results</h3><div>Of 79 742 individuals with hyperlipidemia in <em>AoU</em>, there were 6365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin nonuse (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01–1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, <em>P</em> value < 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05–1.82) and high (aOR = 1.37, 95% CI = 1.09–1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60 to 69 years (aOR = 1.28, 95% CI = 1.05–1.56).</div></div><div><h3>Conclusions</h3><div>Statin use was associated with increased glaucoma likelihood in the overall adult <em>AoU</em> population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60 to 69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one’s lipid profile and age.</div></div><div><h3>Financial Disclosures</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>\",\"PeriodicalId\":19519,\"journal\":{\"name\":\"Ophthalmology. Glaucoma\",\"volume\":\"7 6\",\"pages\":\"Pages 563-571\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Glaucoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589419624001376\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Glaucoma","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589419624001376","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Associations between Statin Use and Glaucoma in the All of Us Research Program
Purpose
To investigate associations between statin use and glaucoma in the 2017 to 2022 All of Us (AoU) Research Program.
Design
Cross-sectional, population-based.
Participants
79 742 adult participants aged ≥40 years with hyperlipidemia and with electronic health record (EHR) data in the AoU database.
Methods
Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by AoU. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.
Main Outcome Measures
Any glaucoma as defined by International Classification of Diseases codes found in EHR data.
Results
Of 79 742 individuals with hyperlipidemia in AoU, there were 6365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin nonuse (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01–1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, P value < 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05–1.82) and high (aOR = 1.37, 95% CI = 1.09–1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60 to 69 years (aOR = 1.28, 95% CI = 1.05–1.56).
Conclusions
Statin use was associated with increased glaucoma likelihood in the overall adult AoU population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60 to 69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one’s lipid profile and age.
Financial Disclosures
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.